Illumina, Regeneron, Intuitive Q4 Results Impress
SAN FRANCISCO — Biotechnology continued to take the spotlight at the JPMorgan Healthcare Conference, as Illumina and Regeneron both offered strong preliminary Q4 results, and the former rolled out two new gene-sequencing products. Meanwhile, beleaguered robotic-surgery firm Intuitive Surgical’s stock rebounded after its Q4 update beat expectations. Illumina (ILMN) CEO Jay Flatley said Q4 revenue rose 25% over the year-earlier quarter to $387